Low-dose S-ketamine and Dexmedetomidine in Combination With Opioids for Postoperative Analgesia
Scoliosis Correction, Postoperative Analgesia, S-ketamine
About this trial
This is an interventional treatment trial for Scoliosis Correction focused on measuring Scoliosis correction, Postoperative analgesia, S-ketamine, Dexmedetomidine, Sufentanil
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years old, body weight ≥ 40 kg;
- Scheduled to undergo scoliosis correction with pedicle screw fixation;
- Planned to use patient-controlled intravenous analgesia after surgery.
Exclusion Criteria:
- Refused to participate in the study;
- Preoperative sick sinus syndrome, severe sinus bradycardia (heart rate < 50 beats/min), atrioventricular block grade II or above without pacemaker; or comorbid with congenital heart disease, arrhythmia, or other serious cardiovascular diseases with a cardiac function grade ≥ III;
- Patients with obstructive sleep apnea syndrome, or a STOP-Bang score ≥ 3 in combination with a serum HCO3- level ≥ 28 mmol/L;
- History of hyperthyroidism and pheochromocytoma;
- History of schizophrenia, epilepsy, myasthenia gravis, or delirium;
- Severe liver dysfunction (child Pugh grade C), severe renal dysfunction (preoperative dialysis), or American Society of Anesthesiologists grade ≥ IV;
- Barrier in communication;
- Other conditions that are considered unsuitable for study participation.
Sites / Locations
- Peking University First Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Combined analgesia group
Control group
Patient-controlled analgesia is established with S-ketamine 50 mg, dexmedetomidine 200 microgram, and sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lock-out interval of 8 minutes and a background infusion rate at 1 ml/h.
Patient-controlled analgesia is established with sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lock-out interval of 8 minutes and a background infusion rate at 1 ml/h.